Stock AnalizPERRIGO Co plc PRGO
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
PERRIGO Co plc (PRGO) is a healthcare company listed in the US with a market value of about $2.3B. In the twelve months to September 26, 2026 it had revenue of $4.1B and net income of -$1.8B, a net margin of -43.3%.
Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is shareholder returns (4/5); the weakest is future growth (0/5).
Key numbers: a price to free cash flow of 13.4, 5-year revenue growth of 1% a year, a 5-year average ROIC of -1%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 45% below the current price.
Score: 1.2 / 5
Checks passed
- P/FCF below 20
- Positive free cash flow
- Pays a dividend
- 20% to 100% of free cash flow returned to shareholders
- Dividend 3 years in a row
- Stock-based pay below 5% of revenue
Checks not passed
- P/E below 25
- P/E below the industry median
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- 3-year free cash flow growth above 10% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.1B | $4.3B | $4.4B | $4.7B | $4.5B | $4.1B | $4.1B | $3.9B | $4.7B | $4.9B | $5.3B |
| Net income | -$1.8B | -$1.4B | -$172M | -$13M | -$141M | -$69M | -$163M | $146M | $131M | $120M | -$4.0B |
| Free cash flow | $168M | $145M | $245M | $304M | $211M | $4M | $466M | $250M | $490M | $610M | $549M |
| EPS (diluted) | $-12.78 | $-10.29 | $-1.25 | $-0.09 | $-1.04 | $-0.52 | $-1.19 | $1.07 | $0.95 | $0.84 | $-28.01 |
| Net margin | -43.3% | -33.5% | -3.9% | -0.3% | -3.2% | -1.7% | -4.0% | 3.8% | 2.8% | 2.4% | -76.0% |
| ROIC | — | -13.1% | 1.1% | 0.9% | 0.8% | 3.7% | 2.2% | 1.5% | 2.1% | 5.0% | -14.1% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 3 analysts is $18.00, 11% above the current price; targets range from $15.00 to $20.00; the consensus rating is “Buy”; expected EPS is $2.35 for the fiscal year ending December 31, 2026.
Frequently asked questions
Is PERRIGO Co stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 45% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does PERRIGO Co pay a dividend?
Yes. The dividend yield is about 7.01%, and it has paid dividends for 10 years in our data.
Is PERRIGO Co a good stock to buy?
We do not give buy or sell advice. PERRIGO Co scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.